PMID- 22906131
OWN - NLM
STAT- MEDLINE
DCOM- 20130620
LR  - 20211021
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 13
IP  - 1
DP  - 2012 Aug 20
TI  - Inflammatory and repair serum biomarker pattern: association to clinical outcomes 
      in COPD.
PG  - 71
LID - 10.1186/1465-9921-13-71 [doi]
AB  - BACKGROUND: The relationship between serum biomarkers and clinical expressions of 
      COPD is limited. We planned to further describe this association using markers of 
      inflammation and injury and repair. METHODS: We studied lung function, 
      comorbidities, exercise tolerance, BODE index, and quality of life in 253 COPD 
      patients and recorded mortality over three years. Serum levels of Interleukins 
      6,8 and16, tumor necrosis factor alpha (TNF alpha) [inflammatory panel], vascular 
      endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP-9) [injury 
      and repair panel] and pulmonary and activation-regulated chemokine (PARC/CCL-18) 
      and monocyte chemotactic protein 1 (MCP-1/CCL2) [chemoattractant panel] were 
      measured. We related the pattern of the biomarker levels to minimal clinically 
      important differences (MCID) using a novel visualization method [ObServed 
      Clinical Association Results (OSCAR) plot]. RESULTS: Levels of the inflammatory 
      markers IL-6, TNF alpha were higher and those of injury and repair lower (p < 0.01) 
      with more advanced disease (GOLD 1 vs. 4). Using the OSCAR plot, we found that 
      patients in the highest quartile of inflammatory and lowest quartile of injury 
      and repair biomarkers level were more clinically compromised and had higher 
      mortality (p < 0.05). CONCLUSIONS: In COPD, serum biomarkers of inflammation and 
      repair are distinctly associated with important clinical parameters and survival.
FAU - Pinto-Plata, Victor
AU  - Pinto-Plata V
AD  - Pulmonary-Critical Care Medicine Division, St Elizabeth's Medical Center, Boston, 
      MA 02115, USA. vpinto@copdnet.org
FAU - Casanova, Ciro
AU  - Casanova C
FAU - Mullerova, Hana
AU  - Mullerova H
FAU - de Torres, Juan P
AU  - de Torres JP
FAU - Corado, Henneth
AU  - Corado H
FAU - Varo, Nerea
AU  - Varo N
FAU - Cordoba, Elizabeth
AU  - Cordoba E
FAU - Zeineldine, Salah
AU  - Zeineldine S
FAU - Paz, Hildegarde
AU  - Paz H
FAU - Baz, Rebeca
AU  - Baz R
FAU - Divo, Miguel
AU  - Divo M
FAU - Cortopassi, Felipe
AU  - Cortopassi F
FAU - Celli, Bartolome R
AU  - Celli BR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120820
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - 0 (Biomarkers)
RN  - 0 (CCL18 protein, human)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines, CC)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-16)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Chemokine CCL2/blood
MH  - Chemokines, CC/blood
MH  - Cohort Studies
MH  - Cytokines/*blood
MH  - Exercise Tolerance/physiology
MH  - Female
MH  - Humans
MH  - Interleukin-16/blood
MH  - Interleukin-6/blood
MH  - Interleukin-8/blood
MH  - Lung/*physiopathology
MH  - Male
MH  - Matrix Metalloproteinase 9/*blood
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/*blood/*physiopathology/psychology
MH  - Quality of Life/psychology
MH  - Respiratory Function Tests
MH  - *Severity of Illness Index
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Vascular Endothelial Growth Factor A/*blood
PMC - PMC3493287
EDAT- 2012/08/22 06:00
MHDA- 2013/06/21 06:00
PMCR- 2012/08/20
CRDT- 2012/08/22 06:00
PHST- 2012/01/25 00:00 [received]
PHST- 2012/07/16 00:00 [accepted]
PHST- 2012/08/22 06:00 [entrez]
PHST- 2012/08/22 06:00 [pubmed]
PHST- 2013/06/21 06:00 [medline]
PHST- 2012/08/20 00:00 [pmc-release]
AID - 1465-9921-13-71 [pii]
AID - 10.1186/1465-9921-13-71 [doi]
PST - epublish
SO  - Respir Res. 2012 Aug 20;13(1):71. doi: 10.1186/1465-9921-13-71.